Comparison of the effects of metoprolol or carvedilol on serum gamma-glutamyltransferase and uric acid levels among patients with acute coronary syndrome without ST segment elevation

In addition, there was no statistically significant difference among the metoprolol or carvedilol groups in terms of uric acid levels measured at the baseline, 1st month, and 3rd month (p=0.601 and p=0.601, respectively).Conclusion: We found that GGT and uric acid levels did not show any change compared to the baseline values, with metoprolol and carvedilol treatment initiated in the early period in patients with NSTEMI

📌 3 Key Takeaways

🎯

Objective & Hypothesis:Objective: Serum gamma-glutamyltransferase (GGT) and uric acid levels measured in patients with acute coronary syndrome without ST segment elevation (NSTEMI) are important in diagnosis and in predicting the prognosis of the disease.

📊

Key Findings & Data:Fifty patients were administered metoprolol succinate treatment (1 x 50 mg), whereas the remaining 50 patients were administered carvedilol treatment (2 x 12.5 mg).

💡

Conclusion & Impact:In addition, there was no statistically significant difference among the metoprolol or carvedilol groups in terms of uric acid levels measured at the baseline, 1st month, and 3rd month (p=0.601 and p=0.601, respectively).Conclusion: We found that GGT and uric acid levels did not show any change compared to the baseline values, with metoprolol and carvedilol treatment initiated in the early period in patients with NSTEMI

🔬Design:Research Article

📍Scope:Comprehensive Sample

⚙️Variables:Domain Parameters

Abstract

Objective: Serum gamma-glutamyltransferase (GGT) and uric acid levels measured in patients with acute coronary syndrome without ST segment elevation (NSTEMI) are important in diagnosis and in predicting the prognosis of the disease. There is a limited number of clinical studies investigating the effects of beta-blockers on GGT and uric acid levels in these patients. In our study, we aimed to investigate the effects of beta-blocker therapy on GGT and uric acid levels.Methods: We conducted a randomized, prospective clinical study. Hundred patients with NSTEMI were included in this study, and they were divided into two groups. Fifty patients were administered metoprolol succinate treatment (1 x 50 mg), whereas the remaining 50 patients were administered carvedilol treatment (2 x 12.5 mg). Thereafter, all of the patients underwent coronary angiography. Blood samples were taken at the time of admission, at the 1st month, and 3rd month to detect GGT and uric acid levels.Results: There was no statistically significant difference among the metoprolol or carvedilol groups in terms of the GGT levels measured at the baseline, 1st month, and 3rd month (p=0.904 and p=0.573, respectively). In addition, there was no statistically significant difference among the metoprolol or carvedilol groups in terms of uric acid levels measured at the baseline, 1st month, and 3rd month (p=0.601 and p=0.601, respectively).Conclusion: We found that GGT and uric acid levels did not show any change compared to the baseline values, with metoprolol and carvedilol treatment initiated in the early period in patients with NSTEMI

🔖

Cite This Article

AŞKIN, L., KARAKELLEOĞLU, Ş., DEĞİRMENCİ, H., DEMİRELLİ, S., ŞİMŞEK, Z., TAŞ, M. H., TOPÇU, S., LAZOĞLU, Z. (2016). Comparison of the effects of metoprolol or carvedilol on serum gamma-glutamyltransferase and uric acid levels among patients with acute coronary syndrome without ST segment elevation. The Anatolian Journal of Cardiology, Cilt: 16 - Sayı: 1, 16–22. https://ajindex.com/articles/365439

📄 Full Text PDF Viewer

Open in New Tab ↗

↗New Tab

📄

PDF görüntüleyici hazırlanıyor...

References (12)

Radovic VV. Use of beta blockers in various clinical states. Med Pregl 2011; 64: 55-60.
Kang JS, Goodman SG, Yan RT, Lopez-Sendon J, Pesant Y, Graham JJ, et al. Management and outcomes of non-ST elevation acute coronary syndromes in relation to previous use of antianginal therapies (from the Canadian Global Registry of Acute Coronary Events [GRACE] and Canadian Registry of Acute Coronary Events [CANRACE]). Am J Cardiol 2013; 112: 51-6.
Duran M, Uysal OK, Yılmaz Y, Günebakmaz O, Arınç H, Topsakal R, et al. Serum gamma glutamyl transferase band the burden of ath- erosclerosis in patients with acute coronary syndrome. Turk Kardiyol Dern Ars 2013; 41: 275-81.
Verdoia M, Barbieri L, Schaffer A, Cassetti E, Nardin M, Bellomo G, et al. Impact of diabetes on uric acid and its relationship with the extent of coronary artery disease and platelet aggregation: A sin- gle-centre cohort study. Metabolism 2014; 63: 640-6.
Bozbaş H, Yıldırır A, Karacağlar E, Demir O, Ulus T, Eroğlu S, et al. Increased serum gamma-glutamyltransferase activity in patients with metabolic syndrome. Turk Kardiyol Dern Ars 2011; 39: 122-7.
Sato Y, Fujiwara H, Takatsu Y. Biochemical markers in heart failure. J Cardiol 2012; 59: 1-7.
Krishnan E, Pandya BJ, Chung L, Dabbous O. Hyperuricemia and the risk for subclinical coronary atherosclerosis data from a prospective observational cohort study. Arthritis Res Ther 2011; 13: 66. Ford ES. Uric acid and mortality from all-causes and cardiovascular disease among adults with and without diagnosed diabetes: findings from the National Health and Nutrition Examination Survey III Linked Mortality Study. Diabetes Res Clin Pract 2011; 93: 84-6.
Ong G, Davis WA, Davis TM. Serum uric acid does not predict cardio- vascular or all-cause mortality in type 2 diabetes: the Fremantle Diabetes Study. Diabetologia 2010; 53: 1288-94.
Niccoli G, Della Bona R, Cosentino N, D'Amario D, Belloni F, Conti MG, et al. Serum levels of glutamyltransferase and progression of coronary atherosclerosis. Coron Artery Dis 2013; 24: 40-7.
Zhu C, Xiong Z, Zheng Z, Chen Y, Qian X, Chen X. Association of serum gamma-glutamyltransferase with arterial stiffness in established coro- nary artery disease. Angiology 2013; 64: 15-20.
Ege MR, Güray U, Güray Y, Demirkan B, Kısacık H. Serum glutam- yltransferase levels correlate with epicardial adipose tissue thickness in patients with coronary artery disease. Angiology 2013; 64: 21-5.
Akpek M, Elçik D, Kalay N, Yarlioglues M, Doğdu O, Şahin O, et a